

FOR IMMEDIATE RELEASE

AMAR International Appoints Dr. David Edward Weng as Senior Medical Officer

Reston, VA. May 17, 2010. AMAR International, Inc. (AMAR) has appointed David Edward Weng, MD, Ph.D., as Senior Medical Officer to work with the company on various programs related to medical oncology and product development.

“We are very pleased to have Dr. David Weng join our distinguished group of AMAR senior professionals who are national and international opinion leaders in their areas of expertise”, commented Dr. John Prakash, Chief Scientific Officer and Senior Vice President at AMAR.

Dr. Weng will serve as Senior Medical Officer at AMAR’s Biomedical Division in Reston, VA, and support the private and government sector programs specialized in product development. Dr. Weng has been involved in the preclinical and clinical programs in medical oncology. His work includes development of ant-cancer products at MediImmune/Astra Zeneca, Cleveland Clinic, Johns Hopkins University and National Cancer Institute. Dr. Weng was Director of Clinical Oncology Development at MedImmune, LLC in Gaithersburg, MD from 2006-09. He was involved with both MedImmune and the parent company AstraZeneca for new drug development and business development. As a component of his drug development experience for both small molecules and biologics in oncology, he led multiple product development teams and collaborations with academic and industry partners.

Before joining the biotechnology industry, Dr. Weng was a staff physician and member of the Department of Hematology and Medical Oncology and the Taussig Cancer Center at the Cleveland Clinic Foundation from 1998-2006. He has been involved in areas of cancer therapeutics development including target selection, preclinical drug development, chemotherapy cytotoxic agents, hormonal therapies, small molecule agents, monoclonal antibodies, cellular therapies, diagnostics, and bioimaging. As an academic participant, Dr. Weng has been involved with multiple biotechnology companies including Ribozyme Pharmaceuticals (now SIRNA), Immunicon (now Veridex), American Bioscience, Inc (now Abraxis Bioscience), Advanced BioPhotonics, Inc., and Genomic Health, Inc. Dr. Weng has been a key opinion leader member of advisory panels and speaker bureaus for Genentech, Sanofi-Aventis, AstraZeneca, Abraxis Biosciences, and Genomic Health Inc. He has been a clinical investigator for 25 oncology studies, with 14 studies as principal investigator. Dr. Weng has over 50 peer-reviewed publications and abstracts in the fields of developmental biology, cancer biology, immunology, and clinical research.

Dr. Weng is a board-certified medical oncologist with a bachelor’s degree in biochemical sciences from Harvard University and medical and doctorate degrees from the Johns Hopkins University School of Medicine. He completed his internal medicine residency training at the Johns Hopkins Hospital, followed by fellowship training in medical oncology at the National Cancer Institute. He continues to maintain active licenses for

Federal DEA prescription privileges for controlled substances and state medical licensure in Maryland and Ohio. He continues to provide direct patient care through locum tenens opportunities in community hematology/medical oncology practices.

About AMAR International, Inc.

AMAR is a program management company specializing in research studies coordination, product development and government programs. The company is dedicated to offering the right solution to federal agencies, pharmaceutical/ biotechnology companies, financial institutions, and clinical research organizations. AMAR's approach is object-oriented; giving the company clients focused knowledge and strategic tools to accomplish their project goals. AMAR International provides tools to manage programs in behavioral and biomedical sciences, subject matter expertise, regulatory affairs for drugs and biologics, QA/QC audits, data coordination tools and services including secure web support for all healthcare programs, biostatistical analysis, program management for clinical and pre-clinical research, and strategic advisory services to the healthcare programs in the federal government as well as to the bioscience companies. AMAR is certified by the United States Government's Small Business Administration (SBA) as 8(a), SDB, and Women Owned company. The company was incorporated in 1999. AMAR's main office is located Reston, Virginia. The office is in close proximity to numerous federal agencies in the Washington D.C. metro area.

Contact Information: Clara Fajutag, MS, AMAR International, Inc., 11440 Commerce Park Dr., Suite 502, Reston, VA 20191, Tel: (703) 476-6700, Ext. 101. Email: clara@amar-international.com